SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Johnson Mark)
 

Search: WFRF:(Johnson Mark) > (2005-2009) > Guideline for the i...

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome

Ariceta, Gema (author)
Besbas, Nesrin (author)
Johnson, Sally (author)
show more...
Karpman, Diana (author)
Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pediatrisk nefrologi,Forskargrupper vid Lunds universitet,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Pediatric Nephrology,Lund University Research Groups
Landau, Daniel (author)
Licht, Christoph (author)
Loirat, Chantal (author)
Pecoraro, Carmine (author)
Taylor, C. Mark (author)
Van de Kar, Nicole (author)
VandeWalle, Johan (author)
Zimmerhackl, Lothar B. (author)
show less...
 (creator_code:org_t)
2009-04-01
2009
English.
In: Pediatric Nephrology. - : Springer Science and Business Media LLC. - 1432-198X .- 0931-041X. ; 24:4, s. 687-696
  • Journal article (other academic/artistic)
Abstract Subject headings
Close  
  • This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome (HUS) is intended to offer an approach based on opinion, as evidence is lacking. It builds on the current ability to identify the etiology of specific diagnostic sub-groups of HUS. HUS in children is mostly due to infection, enterohemorrhagic Escherichia coli (EHEC), Shigella dysenteriae type 1 in some geographic regions, and invasive Streptococcus pneumoniae. These sub-groups are relatively straightforward to diagnose. Their management, which is outside the remit of this guideline, is related to control of infection where that is necessary and supportive measures for the anemia and acute renal failure. A thorough investigation of the remainder of childhood HUS cases, commonly referred to as "atypical" HUS, will reveal a risk factor for the syndrome in approximately 60% of cases. Disorders of complement regulation are, numerically, the most important. The outcome for children with atypical HUS is poor, and, because of the rarity of these disorders, clinical experience is scanty. Some cases of complement dysfunction appear to respond to plasma therapy. The therapeutic part of this guideline is the consensus of the contributing authors and is based on limited information from uncontrolled studies. The guideline proposes urgent and empirical plasmapheresis replacement with whole plasma fraction for the first month after diagnosis. This should only be undertaken in specialized pediatric nephrology centers where appropriate medical and nursing skills are available. The guideline includes defined terminology and audit points so that the early clinical effectiveness of the strategy can be evaluated.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Pediatrik (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Pediatrics (hsv//eng)

Keyword

purpura
Hemolytic uremic syndrome
Complement factor I
Complement factor B
Thrombotic thrombocytopenic
Atypical HUS
member 13 (ADAMTS13)
Plasmapheresis
Complement C3
A disintegrin and metalloproteinase with
co-factor protein MCP (CD46)
Membrane
Enterohemorrhagic Escherichia coli
Complement factor H
a thrombospondin type 1 motif

Publication and Content Type

art (subject category)
vet (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view